Organisation Group: Department for Endocrinology and Radioimmunology
Academic Degree: PhD in Molecular biology
Current position: Research Associate
Education: BSc in Molecular biology and physiology (Master equivalent), course Genetic engineering and Biotechnology, Faculty of Biology, University of Belgrade, Serbia (1999-2004).
Post academic studies in Molecular Biology and Biochemistry, Faculty of Biology, University of Belgrade, Serbia (2004-2006).
PhD in Molecular Biology, Faculty of Biology, University of Belgrade, Serbia (2006-2010). Dissertation Title: “Thyroid peroxidase, galectin-3, HBME-1 and cytokeratin-19 as malignancy and tumor differentiation markers in human thyroid gland”.
Specialization: The Institute of Interdisciplinary Research (Institut de Recherche Interdisciplinaire en Biologie Humaine et Moléculaire, IRIBHM), Université Libre de Bruxelles (ULB), Belgium (2008). Title: “Investigation of TTF-2 phosphorylation in normal thyroid and its expression in undifferentiated thyroid cancer cell lines”.
Tijana Išić Denčić is a member of a team working on the project named: “Molecular characterization of thyroid gland tumors: biological and clinical aspects”. The main goal of the project is to better understand the molecular pathogenesis of thyroid gland tumors, which could open great opportunities for the development of novel molecular-based approaches for the thyroid carcinoma diagnosis/prognosis and optimization of therapy in thyroid carcinomas patients.
Tijana Išić Denčić is working on the identification of novel diagnostic and prognostic molecular markers of thyroid gland tumors, where she mainly focuses on the presence of DNA mutations and changed RNA expressions during the thyroid carcinoma progression.
Membership in International and National Societies:
Serbian Biological Society
Serbian Society for Molecular Biology
Dobrijević Z, Matijašević S, Išić Denčić T, Savić-Pavićević D, Nedić O, Brajušković G. Association between genetic variants in DICER1 and cancer risk: an updated meta-analysis. Gene. 2020; 766: 145132./https://doi.org/10.1016/j.gene.2020.145132
Stojanović S, Šelemetjev S, Đorić I, Rončević J, Janković Miljuš J, Živaljević V, Išić Denčić T: Elevated BANCR expression levels have different effects on papillary thyroid carcinoma progression depending on the presence of the BRAFV600E mutation. Eur J Surg Oncol. 2020; 46 (10): 1835-1842./https://doi.org/10.1016/j.ejso.2020.05.027
Paunović I, Šelemetjev S, Išić Denčić T, Đorić I, Janković Miljuš J, Rončević J, Cvejić D: Coexistence of BRAFV600E mutation and EGFR overexpression is highly associated with adverse clinicopathological features of papillary thyroid carcinoma. Arch Biol Sci. 2019; 72:37-44./https://doi.org/10.2298/ABS190920064P
Rončević J, Đorić I, Šelemetjev S, Janković J, Išić Denčić T, Božić V, Cvejić D. MMP-9 -1562 C/T single nucleotide polymorphism associates with increased MMP-9 level and activity during papillary thyroid carcinoma progression. Pathology, 2019; 51(1): 55-61./doi: 10.1016/j.pathol.2018.10.008.
Išić Denčić T, Bartolome A, Šelemetjev S, Đorić I, Tatić S, Živaljević V, Cvejić D. High expression and localization of β-catenin and epidermal growth factor receptor identify high risk papillary thyroid carcinoma patients. Exp Mol Pathol, 2018; 105:181-189.
Šelemetjev S, Bartolome A, Išić Denčić T, Đorić I, Paunović I, Tatić S, Cvejić D. Overexpression of EGF receptor and its downstream effector, focal adhesion kinase (FAK), correlates with papillary thyroid carcinoma progression. Int J Exp Pathol, 2018; 99:87-94.
Denčić TM, Savin SB, Šelemetjev SA, Paskaš SD, Živaljević VR, Božić VD, Cvejić DS. Strong expression of HBME-1 associates with high-risk clinicopathological factors of papillary thyroid carcinoma. Pathol Oncol Res, 2015; 21:735-742.
Šelemetjev S, Denčić TI, Marečko I, Janković J, Paunović I, Savin S, Cvejić D. Evaluation of survivin expression and its prognostic value in papillary thyroid carcinoma. Pathol Res Pract, 2014; 210:30-34.
Paskaš S, Janković J, Marečko I, Išić Denčić T, Tatić S, Cvejić D, Savin S. Caveolin-1 expression in papillary thyroid carcinoma: correlation with clinicopathological parameters and BRAF mutation status. Otolaryngol Head Neck Surg, 2014; 150:201-209
Išić Denčić T, Cvejić D, Paunović I, Tatić S, Havelka M, Savin S. Cytokeratin19 expression discriminates papillary thyroid carcinoma from other thyroid lesions and predicts its aggressive behavior. Med Oncol, 2013; 30:362-370.